论文部分内容阅读
目的探讨Plk1、Ki67和Survivin在原发性肝细胞癌(HCC)组织中的表达及其临床意义。方法采用免疫组织化学SP法检测60例肝癌组织和20例正常肝组织、肝硬化组织、癌旁组织中Plk1、Ki67和Survivin的表达水平。结果 60例肝癌组织中Plk1、Ki67和Survivin的阳性表达率分别为83.3%(50/60)、76.7%(46/60)、78.3%(47/60),20例正常肝组织、癌旁组织、肝硬化组织中均未见表达。Plk1、Ki67、Survivin在HCC中的表达均与包膜侵犯、癌栓形成及肿瘤转移有关(P<0.05),而与年龄、性别无关。Plk1与Ki67、Survivin与Ki67、Plk1与Survivin的表达相关(P<0.05)。结论 plk1、Ki67、Survivin三者联合检测可为肝癌的诊断和治疗提供新的依据。
Objective To investigate the expression of Plk1, Ki67 and Survivin in primary hepatocellular carcinoma (HCC) and its clinical significance. Methods Immunohistochemical SP method was used to detect the expression of Plk1, Ki67 and Survivin in 60 cases of hepatocellular carcinoma and 20 cases of normal liver tissues, cirrhosis tissues and paracancerous tissues. Results The positive expression rates of Plk1, Ki67 and Survivin in 60 HCC tissues were 83.3% (50/60), 76.7% (46/60), 78.3% (47/60) respectively. Twenty normal liver tissues and paracancerous tissues , No expression in cirrhosis tissues. The expressions of Plk1, Ki67 and Survivin in HCC were all related to envelope invasion, thrombus formation and tumor metastasis (P <0.05), but not to age and sex. Plk1 and Ki67, Survivin and Ki67, Plk1 and Survivin expression (P <0.05). Conclusion The combination of plk1, Ki67 and Survivin could provide new evidence for the diagnosis and treatment of liver cancer.